Taking Aim at Pancreatic Tumors with Immunopeptidomics

Pancreatic cancer is deadly; only about 10% of patients live over five years after they are diagnosed. Patients can be treated in several ways, including with chemotherapy and surgery. Immunotherapies that are known as checkpoint inhibitors do not usually work well, but T cell therapies that aim to attack pancreatic tumors show some potential. Now, scientists have identified cryptic peptides, or small bits of proteins that are generated from parts of the…